Share this article
LUND, Sweden, April 16, 2021 /PRNewswire/
Immunovia s bloodtest IMMray™ PanCan-d was mentioned in the seminar The latest in early detection for pancreatic cancer arranged by Pancreatic Cancer Action Network (pancan.org) on April 15, 2021.
Dr. Rosalie Sears, professor in the department of molecular and medical genetics at Oregon Health and Science University, expressed her enthusiasm for Immunovias bloodtest and the test performance. She was especially impressed by the fact that a non-invasive bloodtest can be used to detect early stages I and II of pancreatic cancer which is crucial for improving treatment outcomes in pancreatic cancer care.
Oregon Health and Science University is one out of 23 centers participating in Immunovia s study PanFAM-1, one of the largest prospective studies to date focusing on early diagnosis in high-risk individuals with Familial/Hereditary Pancreatic Cancer (FPC).
Immunovia reports positive results of the blinded clinical validation of IMMray PanCan-d blood test in USA
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Immunovia reports improved test performance of IMMrayTM PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Immunovia publishes the annual report for the financial year 2020
News provided by
Share this article
LUND, Sweden, March 12, 2021 /PRNewswire/
Immunovia has today published the annual report for 2020. It is available on Immunovia s website
. After many years of intensive preparation, Immunovia is close to a commercial breakthrough with the launch of our blood test for early detection of pancreatic cancer - IMMray™ PanCan-d - in the first quarter of 2021. Thus, Immunovia will be the first company in the world to launch a test that, by virtue of its early detection capabilities, can provide improved care and survival of pancreatic cancer patients, said Patrik Dahlen, CEO Immunovia.